KR100487932B1 - A composition containing Butea superba extract for treating impotence - Google Patents

Abstract

The present invention relates to extracts derived from pueraria myripica, buta superbar and / or mukuna colletti, and methods of extracting the same, foods, beverages, medicines and / or cosmetics containing the extract as an active ingredient, and methods of preparing the same. , The extracts isolated from the plant contains a high concentration of isoflavones, the product made of the composition containing the extract has a very excellent effect of increasing skin elasticity and skin shine when applied to the human body.

Description

A composition containing Butea superba extract for treating impotence

The present invention relates to extracts derived from Pueraria mirifica (White Kwao Krua), Butea superba (Red Kwao Krua), and / or Mucuna collettii (Black Kwao Krua), and extracting methods thereof. It relates to foods, beverages, medicines and / or cosmetics containing the extract as an active ingredient and a method for producing the same.

Pueraria Mirifica is a legume species found mainly in Thailand. It is a tonic herb that has been known in the West in the 1930s and has been transmitted to Thai folks since ancient times (Nature, December 3, 1960, 774). In particular, it is a white edible root plant that has long been used in Thailand as a tonic traditional medicine for postmenopausal women.

Butea superba (red Kwao Krua) is a legume species found mainly in Thailand. In particular, the plant is a long-running plant with red bark that has long been used in Thailand as a tonic traditional medicine for men.

Mucuna collettii (black Kwao Krua) is a large legume species found in subtropical rainforests. This plant usually provides roots. All parts of the plant are cut and turn black when exposed to air. This plant is also used in traditional medicine prescriptions as a tonic for men.

These plants are miroesterol, daidzin, daidzein, genistin, genistein, beta-sitosterol, stigmasterol and stigmasterol. Mestrol (coumestrol), puerarin, campesterol, myrificumestan, mirfuin, kwakhurin, myriphycin, long-chain alcohol, 5-deoxyisoflavone It is composed of more than 25 compounds (Bounds, and Pope, 1960; Ingham et al., 1986a; Ingham et al., 1986b; Ingham et al., 1988). In particular, the plant contains a relatively large amount of phytoestrogens compared to other legumes.

Isoflavones are widely found in common plants, especially in soybeans, soybeans, and alpha beans. Their isoflavones are called phytoestrogens, which derive their name from the fact that these compounds have structures similar to those of endogeneous estrogens in vivo, and that their physiological effects can be equivalent to estrogens. However, when comparing the physiological activities of estrogen and phytoestrogens, phytoestrogens appear to be insignificant compared to estrogens. Only long-term intake of phytoestrogens has been reported to function similar to estrogen hormones (Bingham SA, Atkinson C, J. Nutr 1988 79 (5) 393-406). In view of the kind of phytoestrogens as described above, most of the phytoestrogens are composed of isoflavone-based compounds such as comestrol, genistein, phomonetine, dydzein, and biochanin A.

The notable studies of phytoestrogens so far are: In other words, studies on phytoestrogens involving Japanese women have shown that Japanese women have milder menopausal disorders than Westerners. It is considered to originate from a diet in which soy-related foods high in phytoestrogens are contained. Therefore, many studies have been conducted to improve menopausal disorders using phytoestrogens. For example, Mexican wild horses as precursors of progesterone, an antibody hormone that takes part in the menstrual cycle or takes the phytoestrogens derived from legumes, to improve menopausal disorders and prevent diseases such as breast cancer and cardiovascular disease. There is a product that uses diosgenin extracted from Wild Yam as a cream and applies it to the skin. In particular, research shows that phytoestrogens reduce breast cancer. Asian women are less likely to have breast, ovarian and uterine cancers because they consume longer amounts of phytoestrogens-rich legumes [Adlercreutz H, Honjo H, Am. J. Clin. Nutr. 1991, 54 (6), 1093-1100.

In addition, phytoestrogens have antioxidant activity and have been reported to prevent or improve osteoporosis [Tsutsmi N, Biol Pharm bull 1995, 18 (7), 1012-1015]. Phytoestrogens bind to estrogen receptors in vivo and are therefore believed to have estrogen-friendly or antagonistic effects in tissues. How estrogen is produced in vivo can be explained by the degree of binding to the receptor. In menopause, the amount of estrogen is very small, so the action of phytoestrogens becomes relatively large. In general, phytoestrogens have an activity range of about 1/400 to 1/1000 relative to that of estradiol. However, the activity is so small that no side effects of estrogen are seen. Therefore, many studies have shown that prolonged intake prevents the side effects of estrogen. However, despite many studies, the exact mechanism of action and efficacy of the various diseases related to phytoestrogens have not yet been fully disclosed.

One example of the application of the phytoestrogens as described above is the physiological activity results when the phytoestrogens are applied to the skin. There is a study that observed that when the estrogen is applied to the skin of the menopausal women, the aging of the skin rapidly progresses, the aging of the skin is suppressed. In other words, when estrogen was applied for about 6 months, the elasticity of the skin was remarkably increased and the depth of wrinkles and the like decreased by more than 60%, which is reported to be due to the increase in the number of skin collagen fibers by estrogen [Schmidt]. JB, Binder M, Int J Dermatol 1996, 35 (9), 669-674].

In the skin, elastin tissue is reticulated with collagen and forms a subcutaneous tissue. Elastase is known to play an important role in anti-inflammatory mechanisms as a protease that hydrolyzes elastin. This enzyme non-selectively and indiscriminately hydrolyzes all proteins that serve to maintain the framework and shape of connective tissue, such as elastin, collagen, prothioglycans and keratin. It has also been reported that collagenase enzymes act only on a limited number of substrates [Wiedow, O., Schroder, J.M. , E. J. Biol. Chem. 265 (25), 14791 (1990). The skin that is exposed to UV-A is lightly inflamed repeatedly, which causes the elastase to act on the reticular tissues, causing damage to elastin and collagen fibers and eventually leading to aging of the skin [Motoyoshi, K , Takenouch, M., Proceedings of the 19th IFSCC congress Sydney 22-25, October 1996]. In particular, after the age of 40, the elasticity of the skin is drastically reduced by the action of elastase, which is very active as the action of elastase ages, so that some of the elastin fibers disappear or agglomeration and collagen fibers are reduced. From a biochemical point of view, the activity of elastinase appears to be accelerated with age (Bissett, D. L., Photochem. Photobiol., 1987, 46, 367-378). Recently, many studies have been conducted to find a substance that inhibits the action of the elastase. For example, coated cosmetic products containing elastase inhibitors are disclosed to prevent dry skin caused by UV stimulation or to inhibit skin aging. In particular, since plant extracts with antioxidant power generally have an inhibitory effect on elastase, many studies have been conducted to prevent skin aging and wrinkles by applying this [Bizot-Foulon V., Godeat G., W. Int . J. Cos. Sci. 17,255 to 264 (1995).

The inventors have found that a Fueraria myripica, buta superbar or mukuna colletti plant with at least 40-fold and up to 100-fold estradiol activity compared to other legumes, i.e., contains phytoestrogens of about 0.5 IU or more It was closely related to the effect on the basal layer of the skin and was primarily tested in vitro.

In general, the phytoestrogens activity of legumes ranges from about 1 / 20,000 to 1/50 I.U. (* 1 I.U. = 0.1 mg of estradiol). However, because the phytoestrogens content (about 0.5 IU) of pueraria myripica, buta superbar and mukuna colletti are relatively high, the anti-elastinase inhibitory activity is expected to be high. Indicated.

The present inventors note that pueraria myripica, buta superbar and mukuna colletti do not have high antioxidant activity levels but have a high degree of inhibition of elastase. In particular, the present invention was completed by preparing a cosmetic composition for maintaining skin elasticity and applying the cosmetic composition to human skin to evaluate skin elasticity and shine.

It is therefore an object of the present invention to provide extracts derived from pueraria myripica, buta superbar and / or mukuna colletti.

Another object of the present invention is to provide a method for extracting the extracts derived from the pueraria myripica, buta superbar and / or mukuna colletti.

Still another object of the present invention is to provide a food, beverage, medicine and / or cosmetics containing the extract of Pueraria myripica, buta superbar and / or mukuna colletti as an active ingredient.

Still another object of the present invention is to provide a method for preparing food, beverage, medicine and / or cosmetics containing the extract of Pueraria myripica, buta superbar and / or mucuna colleti derived as an active ingredient.

In order to achieve the above object, extracts derived from Pueraria myripica, buta superbar and / or mukuna choleti according to the present invention are roots of the plant of Pueraria myripica, buta superbara and / or mukuna choleti Callus by root, stem, leaf or tissue culture is characterized in that it is extracted using water, an organic solvent or a mixed extractant.

Extraction method for achieving another object of the present invention, the oven and the temperature and time of the callus by the root, root, stem, leaf, tissue culture of pueraria myripica, buta superbar and / or mucuna colletti And then pulverized and then pulverized, extracted using water, an organic solvent or a mixed extractant, and then spray-dried, lyophilized and / or vacuum-dried the extract.

Method for producing a food, beverage, pharmaceutical and / or cosmetic product for achieving another object of the present invention. Callus by root, root, stem, leaf, and tissue culture of pueraria myripica, buta superbar and / or mucuna colletti is dried in a temperature and time-controlled oven, pulverized, and extracted with an extractant Drying the extract to prepare an extract; And a solvent such as water, a low molecular alcohol having one or more hydroxyl groups or a synthetic solvent, and the extract alone or in combination with other extracts and / or bases, diluents, additives, colorants, active agents, surfactants, moisture agents, anti-aging agents Or it is characterized in that the mixture of 0.1 to 99.9% by weight or 0.1 to 99.9% by weight or volume% of the cosmetic raw material and the total amount.

Here, the product contains a powder, dry or water-soluble extract or substance in an amount of 0.1 to 100%, preferably in the form of pills, capsules, packages, bottles, boxes or other packaging. In addition, the extract is advantageous in that further added calcium inorganic or high calcium organic matter. The drying process is preferably performed for 2 to 9 hours in an oven at a temperature of 40 ~ 90 ℃.

In order to achieve another object of the present invention, powders, dried extracts, extracts and / or bioactive compounds isolated from raw materials such as pueraria myripica, buta superbar, mukuna colletti, skin care and / or breast Manufacture of health foods, nutraceuticals, beverages, drugs for care, breast enhancement, breast fixation, breast enlargement and breast wrinkle removal cosmetics, functional cosmetics, medicinal cosmetics and drugs, and / or for the treatment of prostate thickening, and / Or to prepare high cholesterol, foods, beverages and drugs to prevent atherosclerosis, and / or to manufacture foods, beverages and drugs for erectile dysfunction, erectile dysfunction in men, and / or to treat menopausal and postmenopausal syndromes. It can be used in the manufacture of foods, beverages, drugs.

Hereinafter, the configuration of the present invention will be described in detail through examples and test examples, but the scope of the present invention is not limited only to these examples.

Example 1: Preparation of pueraria myripica extract

100 g of pueraria myripica root was washed and dried at 70 ° C. for about 5 hours using a hot air dryer and then ground. 500 mL of methanol / water (80/20 v / v) was added to the pulverized product and extracted at 50 ° C. for about 6 hours. The extract was filtered, concentrated under reduced pressure to remove the solvent, and the concentrate was lyophilized to prepare a brown solid, and the content of isoflavone in the solid was measured. As a result, the amount of isoflavones contained in the prepared pueraria myripica root extract was as shown in Table 1.

Isoflavone Content in Pueraria Myripica Root Extract. Isoflavones mg / 100g Didizin 51.0 Daad Jane 8.1 Jennysteen 12.0 Zenithstein 2.0 Puerin 96.0

The inventors have found that the highest quality pueraria myripica powder can be obtained by the above method. The powder obtained by the above method showed a high content of isoflavones and other phytoestrogens.

As a result, phytoestrogens obtained from the above plants were labysterol, dydzin, dydzein, genistin, genistein, beta-sitosterol, stigmasterol, cumestrol, puerarin, campestrol, myripicumestan, Hurin, myriphycin (Bounds, and Pope, 1960; Ingham et al., 1986a; Ingham et al., 1986b; Ingham et al., 1988).

Isoflavones are particularly potent anticancer agents for breast, colon and prostate cancers. The high content of isoflavones in the Pueraria myripica powder prepared in the present invention is very beneficial to humans.

Moreover, chemical extraction of a high isoflavone profile from pueraria myripica involves thinning or powdering the plant in all parts of the plant, including roots, rhizomes, leaves, stems, callus, cell cultures, root cultures, It is successfully found when mixed with a solvent consisting of water and a low molecular alcohol having one or more hydroxyl groups or a synthetic solvent using possible standard techniques. The extract can be used directly or used to concentrate to produce more purified and / or higher concentration extracts.

Example 2: A lotion containing pueraria myripica extract

In this embodiment, as shown in Table 2, 4.0% by weight of pueraria myripica extract, 4.0% by weight of butylene glycol, 0.001% by weight of ethylenediaminetetraacetate, 0.01% by weight of citric acid, 15.0% by weight of ethanol, 0.1% of paraoxybenzoic acid methyl %, Polyoxyethylene sorbitan monostearate 0.5% by weight, fragrance 0.2% by weight and the remainder was prepared a cosmetic composition containing purified water. The method is first dissolved in the oil and water components in a separate dissolution tank in the emulsifying unit After emulsification together, the mixture was cooled to 30 ° C and aged.

Constituent composition of the lotion containing pueraria myripica extract. ingredient content Pueraria Mirifica Extract 4.0 Butylene glycol 4.0 Sodium Ethylenediaminetetraacetate 0.001 Citric acid 0.01 ethanol 15.0 Methyl paraoxybenzoate 0.1 Polyoxyethylene sorbitan monostearate 0.5 Spices 0.2 Purified water TO 100 [Note] Unit: wt%

Example 3: Lotion Containing Pueraria Myripica Extract

In this example, a lotion containing the Pueraria myripica extract was prepared in the same manner as in Example 2, and the composition of the lotion was as shown in Table 3.

Example 4: Essence Containing Pueraria Myripica Extract

In this example, an essence containing pueraria myripica extract was prepared in the same manner as in Example 2, and the composition of the essence was as shown in Table 4.

Composition of ingredients of lotion containing pueraria myripica extract. ingredient content Pueraria Mirifica Extract 4.0 Cetostearyl alcohol 1.0 Glyceryl Monostearate 0.8 Sorbitan monostearate 0.3 Propylparaben 0.1 Polysorbate 60 1.0 Mineral oil 5.0 Pyromethicone 3.0 Dimethicone 0.5 Allantoin 0.1 glycerin 5.0 Propylene glycol 3.0 Methylparaben 0.2 Triethanolamine 0.2 Carbomer 8.0 Purified water TO 100 [Note] Unit: wt%

Constituent composition of the essence containing pueraria myripica extract. ingredient content Pueraria Mirifica Extract 6.0 Butylene glycol 4.0 glycerin 3.0 Milk extract 1.0 Allantoin 0.1 Panthenol 0.1 Sodium Ethylenediaminetetraacetate 0.01 Carbomer 0.15 Collagen aqueous solution 0.5 ethanol 6.0 Polyoxyethylene octyldodecyl ether 0.3 Methyl Parabenzoate 0.1 Triethanolamine 0.15 Purified water TO 100 [Note] Unit: wt%

Example 5 Cream Containing Pueraria Myripica Extract

In this example, a cream containing a pueraria myripica extract was prepared in the same manner as in Example 2, and the composition of this essence was as shown in Table 5.

Ingredient composition of a cream containing pueraria myripica extract. ingredient content Pueraria Mirifica Extract 4.0 Cetostearyl alcohol 1.0 Glyceryl Monostearate 1.0 Sorbitan monostearate 0.3 Microcrystalline Lead 0.2 Propylparaben 0.1 Petrolatium 1.0 Polysorbate 60 1.0 Mineral oil 5.0 Pyromethicone 3.0 Dimethicone 0.5 Avocado Oil 2.0 Allantoin 0.1 glycerin 5.0 Propylene glycol 3.0 Methylparaben 0.2 Triethanolamine 0.2 Carbomer 17.0 Xanthan Gum 0.1 Purified water TO 100 [Note] Unit: wt%

Test Example 1: Human application of the skin cosmetic composition of the present invention

In this test example, the cream containing the pueraria myripica extract of the present invention prepared in Example 5 was applied to the human body, and the skin elasticity and moisture enhancement were evaluated.

Human application results of the skin cosmetic composition of the present invention. Pt. No. Treatment Pre Tx (mm) Post Tx (mm) One 0.645 0.968 2 0.824 0.878 3 0.737 0.923 4 0.969 One 5 0.917 0.935 6 0.875 0.923 7 0.97 0.905 8 0.976 0.951 9 0.951 0.878 10 0.897 1.048 11 0.947 0.939 12 0.906 0.952 13 0.931 0.966 14 0.938 0.944 15 0.926 One 16 0.895 0.824 17 0.794 0.888 18 0.895 0.895 19 0.889 0.9444 20 0.933 0.974 21 0.938 0.889 22 0.8 0.82 23 0.889 0.81 24 0.967 0.965 25 0.929 0.923 26 0.931 0.939 27 One 0.882 28 0.875 0.84 29 0.903 0.951 30 0.964 One 31 0.967 0.970 32 0.84 0.941 33 0.811 0.742 34 0.869 One 35 0.821 0.824 36 0.517 0.889 37 0.771 0.967 38 0.880 0.968 39 0.875 0.882 Pt. No. Placebo Control Pre Tx (mm) Post Tx (mm) One 0.95 0.9 2 0.794 0.95 3 0.867 0.933 4 0.816 0.842 5 0.938 0.971

Paired T-test value. Treatment Pre TX Post Tx Average 0.881076923 0.921471795 Dispersion 0.008956336 0.004016681 Observations 39 39 Pearson's Correlation Coefficient 0.232602588 Hypothesis mean difference 0 Degrees of freedom 38 t statistic -2.499917473 P (T <= t) one-sided test 0.008428418 t rejection one-sided test 1.685953066 P (T <= t) Bilateral Test 0.016856836 t-sided two-sided test 2.024394234 Control Pre Tx Post Tx Average 0.873 0.9192 Dispersion 0.00492 0.0025377 Observations 5 5 Pearson's Correlation Coefficient 0.266946433 Hypothesis mean difference 0 Degrees of freedom 4 t statistic -1.384052624 P (T <= t) one-sided test 0.119277841 t rejection one-sided test 2.131846486 P (T <= t) Bilateral Test 0.238555682 t-sided two-sided test 2.776450856

Forty-four healthy women in their twenties to fifties were tested. Thirty-nine people applied a cream containing pueraria myripica and five applied a cream containing no pueraria myripica as a control. The application period was 2 months, and about 1g of cream was applied evenly over the entire breast area in the morning and evening. Initial application was started on the 3rd to 5th day after the menstruation of each subject began, and the elasticity of the breast was measured. After 2 months, breast elasticity was measured on the 3rd to 5th day after the subject's menstruation began. Elasticity measurement was measured by using a cutometer SEM474 (Courge + Khazaka electronic GmbH, Inc.) 1cm away from the center of the teat at 12 o'clock, the results are shown in Table 6 and Table 7.

The null hypothesis that there is no difference in elasticity before and after application

Assuming an alternative hypothesis that elasticity occurs after application,

The P value of the one-sided test of the treatment group coated with the pueraria myripica-containing cream was <0.05, and accordingly the null hypothesis was rejected, indicating that the elasticity of the breast was significantly shown. Although the control group coated with a cream containing no Pueraria myripica was not statistically easy due to the small number of observations, the P-value of the one-sided test was> 0.05, so the null hypothesis was not rejected and there was no difference in breast elasticity. Able to know. Simultaneously with the measurement of elasticity, the size of the breast was taken by MRI to obtain its volume, and a clinical trial was performed to determine whether the size of the breast increased. As a result, the statistical value was not significantly increased.

Test Example 2: Application of the food supplement or functional food to the human body before menopause

As shown in Table 8 below, clinical trials as food supplements and functional foods were conducted for 97 healthy (premenopausal) people aged 20 to 45 years.

A placebo group of 31 subjects (without pharmacological action but only for the patient's mental comfort) should consume 2 capsules daily for 15 days a month beginning on the first day of menstruation for two consecutive months. Tapioca starch capsules were taken.

Validation of pueraria myripica consumed as food supplement or functional food in premenopausal women. Placebo 400 mg / day 800 mg / day Number of subjects 31 32 34 Breast pain 31 14 32 Skin recovery 31 28 32 Hair improvement 31 24 30 Charasma clearness - 3/3 4/4 Secretion improvement 31 14 29 Menstrual improvement 31 2 10 Breast elasticity 31 13 30 Breast enlargement 31 3 28 Pelvic enlargement 31 3 20

All recorded parameters of this group did not show significant changes. The first experimental group, which included 32 subjects, took 200 mg of Pueraria myripica capsules to consume two capsules per day under the same conditions as the placebo group. Breast pain (44%), skin recovery (88%), healthier hair (75%), charisma clearness (100%), vaginal secretion, 44 %), Healthy menstruation (6%), induced fixation (44%), breast enlargement (9%), and enlargement of the buttocks (9%), all of the recorded parameters of this group showed various values and showed large changes.

The second experimental group, including 34 subjects, consumed 200 mg of Pueraria myripica capsules to consume four capsules per day under the same conditions as the placebo group.

All recorded parameters in this group including breast pain (94%), skin recovery (94%), healthier hair (88%), charisma clearness (100%), vaginal secretion (85%) Is high and shows a significant change, so in some subjects women's sexual function, breast pain (29%), induced fixation (94%), breast enlargement (88%) and hip enlargement (59%) recover It became. Some subjects also reported reduced hyperglycemic cholesterol levels.

In conclusion, clinical trials as food supplements or functional foods showed clear estrogenic effects in subjects, including inducing skin improvement, hair complexity, induced fixation and breast enlargement.

Test Example 3: Human application of postmenopausal women of the present invention food supplement or functional food

Pueraria myripica was molded into food supplements or functional foods for postmenopausal women. Six postmenopausal women took 200 mg of Pueraria myriquipa capsules once daily, 21 days a month for four consecutive months. Physical examination and blood analysis were performed immediately before and after the experiment.

Subjects ranged from 35 to 58 years of age with high fever, paranoia, dry skin and menstruation. The experimental results are shown in Table 9.

As a result, the intake of pueraria myripica as a food supplement or a functional food showed an excellent therapeutic effect on menopausal symptoms such as high fever, paranoia, dry skin and poor menstruation.

Validation of pueraria myripica intake as a food supplement or functional food in postmenopausal women. Subject age Before Intake After ingestion Symptoms Menstruation Symptoms Menstruation One 46 High fever stoppage normal stoppage 2 52 High fever stoppage normal stoppage 3 35 Dry skin disappearance normal Appearance 4 58 High fever stoppage normal stoppage 5 49 High fever continuing normal continuing 6 39 Paranoia Almost none normal normal

Test Example 4: skin allergy test of pueraria myripica extract

The skin allergy test of Pueraria myripica was conducted on six Wistar rats and six rabbits. The experimental results are shown in Table 10.

Skin allergy screening of pueraria myripica extract in Wistar rats and rabbits. animal Wistar Rat rabbit 1st reaction Allergic reaction Allergic reaction Secondary reaction Allergic reaction Allergic reaction

As a result, it was found that Pueraria myripica can be safely applied to human skin since it did not cause primary and secondary allergic reactions on the skin of animals.

Example 6 Preparation of Bueta Superva Extract

After washing 100 g of root root of Bueta super bar, it was dried at 70 ° C. for about 5 hours using a hot air dryer, and then ground. 500 mL of methanol / water (80/20 v / v) was added to the pulverized product and extracted at 50 ° C. for about 6 hours. The extract was filtered and concentrated under reduced pressure to remove the solvent, and the concentrate was lyophilized to give a brown solid.

Test Example 5: Validation of butaperva as a food supplement or functional food

Clinical trials of buta superbars as food supplements or functional foods were conducted in 142 patients with erectile dysfunction aged 20 to 55 years.

The first group received 200 mg of tapioca starch as a placebo, one capsule each after breakfast and dinner. The second group consumed 200 mg of Buttea superba capsules after breakfast and dinner, one capsule each after breakfast and dinner. The third group consumed 200 mg of Buta superbar capsules, two capsules each after breakfast and dinner. As shown in Table 11, eight parameters were evaluated.

In Table 11, five subjects were discontinued on Days 3-4 due to adverse effects (2: sore throat, 3: back pain). One subject was permanently discontinued, and four subjects continued with no further adverse effects after supplementing with fresh milk daily.

Validation of butane superbar as a food supplement or a functional food for men with erectile dysfunction for 2 months. Placebo 400 mg / day 800 mg / day Number of subjects 42 46 54 Early erection (mean ± S.D.) 0 7.41 ± 1.12 4.16 ± 0.81 Immediate erection 0 32 43 (+4) Continuous erection 0 28 42 (+4) Maintain erection for at least 2 minutes after ejaculation 0 14 29 (+4) Significantly increased weekly 0 32 43 (+4) Significantly increased weekly 0 11 20 (+2) Increased sexual satisfaction 0 32 43 (+4)

When buta superbar was mixed or replaced with mukuna colletti, the recovery effect on erectile dysfunction was greater. In the present invention, it is possible to produce products containing buta superbar and mukuna colletti for the above purpose.

In conclusion, the buta super bar powder prepared by the above-mentioned method has been proved to be an effective herbal medicine for male sexual function, especially through a strong vasodilation effect on the penis. Through this mechanism, buta superbar can be used directly or as a major part of herbal products for the treatment of male erectile dysfunction.

To test this hypothesis, 65 volunteers with no impaired erection were divided into two groups. The first group received two capsules of 200 mg of tapioca powder placebo for two months after breakfast and dinner, and the experimental group consumed buta superbar by the same method with the same size. The experimental results are shown in Table 12.

Validation of Butane Superbar in Erectile Dysfunction Men. Number of subjects Recovery Placebo 31 2 Experiment 34 28

The recovery in the placebo group was due to psychological effects, while the experimental group showed significant recovery.

In addition, there were no symptoms of prostate thickening in both groups of erectile dysfunction and erectile dysfunction. These results were mainly due to β-sitosterol present in this herb and reported as a potent prostatic thickening inhibitor (Klippel et al. 1997). These evidences confirm that buta superbar can be prepared as a prostate thickening preventive drug or health food. It can also be mixed or replaced with Mucuna colletti for the purpose of a stronger reaction. As a result, buta superbars can be made into herbal based products for use as therapeutic agents for erectile dysfunction.

Test Example 6 Skin Allergy Test of Butasperva Extract

Butte superbar extract was applied to the skin of rats for allergy testing. The experimental results are shown in Table 13.

Skin allergy test in six rats. Primary allergic reaction None Secondary allergic reaction None

In this experiment, it was confirmed that the buta superbar extract is safe to apply to the skin or to develop an external product of cosmetics or medicines.

Test Example 7: Validation of Buta superbar gel in erectile dysfunction men

To evaluate the effectiveness of the Buta superbar extract as an agent for erectile dysfunction, 63 subjects were divided into two groups: placebo and experimental group. The placebo group supplied a gel that did not contain buta superbars directly to the penis twice daily for a month. In addition, the experimental group prescribed the gel containing butasperva extract in the same manner as the placebo group. The experimental results are shown in Table 14.

Recovery from the placebo group may be due to psychological effects, or massage during gel application may have facilitated such effects. As a result, it is also possible to prepare external products for erectile dysfunction or erectile dysfunction from buta superbars.

Validation of Butane Superbar Gel in Erectile Dysfunction Men. Number of subjects Recovery Placebo 31 One Experiment 32 21

The preparation of the powders of Pueraria myripica and Buta superbar can also be applied to this plant. The powder has very high vasodilation activity and no severe adverse effects.

Chemical extracts of these three herbs are mixed with water, solvents consisting of low molecular alcohols with one or more hydroxyl groups, or synthetic solvents using possible techniques, and then cut into thin layers, including roots, rhizomes, stems, leaves, and callus by culture. Found successfully in all parts of the plant.

This extract is easily homogenized by mixing with other compounds or bases used in cosmetics or trauma drugs. It can be used as an external medicine used as a cosmetic or medicine. The permeability of the new mixture is still very high.

We tested three herbal extracts with high water pressure. The product is easily mixed with the other ingredients used to make the beverage.

The present inventors also tested powder preparation or extract preparation using spray drying, freeze drying and vacuum drying. High quality powders and / or extracts could be obtained in all of the above preparations.

In addition, by chemical extraction prior to evaporation, a pure, ie high concentration mixture of the chemicals isolated from the plant, which is a good material for herbal medicine and drug preparation, can be obtained. The product separated by this method shows high effectiveness.

As described above, the pueraria myripica, buta superba and / or mukuna colletti extracts of the present invention contain a high concentration of isoflavones and a product prepared from the composition containing the extract. This is a very useful invention in the food, beverage, pharmaceutical and cosmetics industry because it has a very excellent effect of increasing skin elasticity and skin shine in human application.

Claims (2)

Erectile dysfunction and erectile function characterized in that the root of the buta super bar containing buta super bar extract extracted using a mixed solvent of water and a lower alcohol having 1 to 5 carbon atoms having one hydroxyl group as an active ingredient Composition for the treatment of disorders. The erectile dysfunction and erectile function of claim 1, wherein the lower alcohol is selected from methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methylpropanol, and 2-methyl-2-propanol. Composition for the treatment of disorders.